These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 34544951)

  • 1. A Rare Case of Rheumatoid Arthritis with Tocilizumab-induced Intestinal Mucosal Injury.
    Ohkubo A; Osoegawa T; Harada N; Iboshi Y; Sumida Y; Nakamuta M; Suematsu E; Kobayashi H; Ihara E
    Intern Med; 2022 Apr; 61(7):1011-1014. PubMed ID: 34544951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis.
    Iwasa T; Nakamura K; Ogino H; Itaba S; Akiho H; Okamoto R; Iboshi Y; Aso A; Murao H; Kanayama K; Ito T; Takayanagi R
    Endoscopy; 2011 Jan; 43(1):70-2. PubMed ID: 21108178
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis.
    Palmou-Fontana N; Sánchez Gaviño JA; McGonagle D; García-Martinez E; Iñiguez de Onzoño Martín L
    Dermatology; 2014; 228(4):311-3. PubMed ID: 24942661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab-induced psoriasis-like eruption resolved by shortening the dose interval in a patient with rheumatoid arthritis: a case-based review.
    Hayakawa M; Izumi K; Higashida-Konishi M; Ushikubo M; Tsukamoto M; Akiya K; Araki K; Oshima H
    Rheumatol Int; 2019 Jan; 39(1):161-166. PubMed ID: 30357484
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Erysipelas without fever or biologic inflammation during tocilizumab therapy].
    Yéléhé-Okouma M; Henry J; Petitpain N; Schmutz JL; Gillet P
    Ann Dermatol Venereol; 2017; 144(6-7):434-437. PubMed ID: 28396064
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: case series and review of literature.
    Shovman O; Shoenfeld Y; Langevitz P
    Immunol Res; 2015 Feb; 61(1-2):164-8. PubMed ID: 25403696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Persistent aphthous mouth ulcers associated with tocilizumab: two cases].
    Samimi M; Lauferon F; Hüttenberger B; Vaillant L; Goupille P; Machet L
    Ann Dermatol Venereol; 2013 Feb; 140(2):120-4. PubMed ID: 23395494
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation.
    Chen LF; Mo YQ; Jing J; Ma JD; Zheng DH; Dai L
    Int J Rheum Dis; 2017 Jul; 20(7):859-869. PubMed ID: 28160426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agranulocytosis under biotherapy in rheumatoid arthritis: three cases hypothesis of parvovirus B19 involvement in agranulocytosis observed under tocilizumab and rituximab for the treatment of rheumatoid arthritis.
    Giraud C; Tatar Z; Soubrier M
    Clin Rheumatol; 2016 Oct; 35(10):2615-8. PubMed ID: 27541023
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety of subcutaneous versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with rheumatoid arthritis.
    McLaughlin M; Östör A
    Expert Opin Drug Saf; 2015 Mar; 14(3):429-37. PubMed ID: 25553607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY).
    Dougados M; Kissel K; Sheeran T; Tak PP; Conaghan PG; Mola EM; Schett G; Amital H; Navarro-Sarabia F; Hou A; Bernasconi C; Huizinga TW
    Ann Rheum Dis; 2013 Jan; 72(1):43-50. PubMed ID: 22562983
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
    Ogata A; Kato Y; Higa S; Yoshizaki K
    Mod Rheumatol; 2019 Mar; 29(2):258-267. PubMed ID: 30427250
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use and effectiveness of tocilizumab among patients with rheumatoid arthritis: an observational study from the British Society for Rheumatology Biologics Register for rheumatoid arthritis.
    Kihara M; Davies R; Kearsley-Fleet L; Watson KD; Lunt M; Symmons DP; Hyrich KL;
    Clin Rheumatol; 2017 Feb; 36(2):241-250. PubMed ID: 27913894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effectiveness, therapeutic maintenance and reasons for stopping tocilizumab (TCZ): A retrospective and monocentric study in 88 patients followed for rheumatoid arthritis (RA) at the Reims university hospital].
    Chopin C; Pauvele L; Jaulerry S; Brochot P; Eschard JP; Salmon JH
    Therapie; 2018; 73(3):231-236. PubMed ID: 29146040
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.
    Pawar A; Desai RJ; Solomon DH; Santiago Ortiz AJ; Gale S; Bao M; Sarsour K; Schneeweiss S; Kim SC
    Ann Rheum Dis; 2019 Apr; 78(4):456-464. PubMed ID: 30679153
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The efficacy and safety of reinstitution of tocilizumab in patients with relapsed active rheumatoid arthritis after long-term withdrawal of tocilizumab: retreatment of patients with rheumatoid arthritis with novel anti-IL-6 receptor antibody after a long-term interval following SAMURAI: the RONIN study.
    Sagawa A
    Mod Rheumatol; 2011 Aug; 21(4):352-8. PubMed ID: 21347804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized, double-blind, parallel-group, phase III study of shortening the dosing interval of subcutaneous tocilizumab monotherapy in patients with rheumatoid arthritis and an inadequate response to subcutaneous tocilizumab every other week: Results of the 12-week double-blind period.
    Ogata A; Tanaka Y; Ishii T; Kaneko M; Miwa H; Ohsawa S;
    Mod Rheumatol; 2018 Jan; 28(1):76-84. PubMed ID: 28622048
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study.
    Kim SC; Solomon DH; Rogers JR; Gale S; Klearman M; Sarsour K; Schneeweiss S
    Arthritis Rheumatol; 2017 Jun; 69(6):1154-1164. PubMed ID: 28245350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of extending intravenous tocilizumab intervals from 4 to 6 weeks in rheumatoid arthritis patients with good response to 4-week intervals.
    Saiki O; Uda H
    Rheumatol Int; 2018 Dec; 38(12):2307-2313. PubMed ID: 30206670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and effectiveness of subcutaneous tocilizumab in patients with rheumatoid arthritis in a real-world clinical setting.
    Atsumi T; Fujio K; Yamaoka K; Tomobe M; Kuroyanagi K; Kameda H
    Mod Rheumatol; 2018 Sep; 28(5):780-788. PubMed ID: 29251032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.